DayTwo develops a precision nutrition solution combining gut microbiome profiling, AI that predicts blood sugar responses to foods, and dedicated virtual care. The company focuses on metabolic diseases—diabetes, prediabetes, and clinical obesity—and sells programs to employers, health plans, and health systems. DayTwo says it holds the world's largest and richest proprietary gut microbiome dataset and notes NIH citation of its scientific research. Participants in DayTwo programs report sustained clinical outcomes, including more than a 1.4-point reduction in A1C, a 69% improvement in Time in Range, an average 18-pound weight loss, a 3.3-point reduction in BMI, and significant reduction or elimination of medications. DayTwo announced $37 million in new funding to accelerate expansion of its chronic disease solutions and virtual care offerings, bringing total funding to $85 million. The company plans to apply its science and IP to improve outcomes for other diseases in addition to metabolic conditions. Leadership changes announced alongside the financing include the appointment of David Henderson as CEO and John Watts, Jr. to the board. DayTwo operates a microbiome human discovery platform with an actionable product on the market that delivers personalized dietary interventions. Its platform is built on a large full-shotgun database of gut-microbiome profiles worldwide and follows a food-as-medicine approach based on research by Professors Eran Segal and Eran Elinav at the Weizmann Institute, published in Cell in 2015. The Cell paper demonstrated how the gut microbiome together with clinical and personal parameters can enable personalized dietary interventions to balance post-meal glucose response. DayTwo has offices in Tel Aviv and the San Francisco Bay Area and is led by CEO and Founder Lihi Segal. The company has 85 employees. It is currently expanding its Series B financing with strategic investments from Longliv Ventures, Cathay Innovation and Samsung NEXT. DayTwo offers a glycemic control solution that uses gut microbiome profiling and other clinical parameters to deliver a food-as-medicine approach. Its product provides actionable insights into how individuals metabolize specific foods and meals to help balance blood sugar. The approach is based on research from the Weizmann Institute published in Cell in 2015. DayTwo reported tens of thousands of individual customers, hundreds of providers in its clinician network, and employs 75 people; it also has a strategic partnership with Clalit to offer its solution to 4.5 million members. Ongoing clinical and research partners include the Weizmann Institute, the Israel Diabetes Association, Joslin Diabetes Center, Janssen (Johnson & Johnson), and the Mayo Clinic. The company plans to use new funding to accelerate U.S. go-to-market efforts and to develop a new generation of products and services for metabolic and gastrointestinal conditions. DayTwo sends users at-home test kits to perform genetic analysis of their gut microbiome and delivers actionable, personalized dietary and exercise recommendations via a mobile app. The consumer product is available for pre-order, with kits priced at $299 and shipping planned by the end of July. The company also plans to offer its platform as a service to provider organizations to support patients for whom nutrition is especially important. Its technology is based on five years of research by Prof. Eran Segal and Dr. Eran Elinav at the Weizmann Institute of Science. DayTwo is already collaborating with the Mayo Clinic on a research project that will be expanded with the new funding. To date the startup has raised $17 million in total.

Total raised

$85M

Funding rounds

4

Latest round

Equity

Latest activity

Aug 2021